COVID-19 InfectionNCT04682912
Blood Types in Children With COVID-19
An observational study of COVID-19 Infection, run by Mersin Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
It is speculated that in adult patients with COVID-19 blood type A is associated with the worst outcome, while blood type O is associated with mild symptoms.To our knowledge, there has been no such a study investigated ABO and Rhesus (Rh) blood group types in children with COVID-19 infection yet. Read more about this study
- Who is it for?
- Ages 1 month to 18 years
- Conditions the study is for
- COVID-19 Infection
- How many people
- 2,000 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 30 Jan 2021to Feb 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: A retrospective multicenter trial in five major hospitals in Turkey to determine whether ABO and Rh blood types carry any risk/beneficial factor among children with COVID-19 infection.
Who may be able to join
- The study period consisted between March 2020 and December 2020
- Children with a documented positive COVID-19 nasal smear real-time reverse-transcriptase polymerase chain reaction (PCR) assay were included.
Who cannot join
- Patients who had a past medical history of any chronic illness (related to respiratory, cardiology, immunology, neurology, metabolic, etc) were excluded.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Mersin City Training & Research Hospital
Mersi̇n, 33240
Ali̇ Özdemi̇r, MD, 03242251000, aliozdemir@hotmail.com
About this study
Official title: ABO-Rh Blood Types and COVID-19 Infection in Children: Is There a Link?
It is speculated that in adult patients with COVID-19 blood type A is associated with the worst outcome, while blood type O is associated with mild symptoms.To our knowledge, there has been no such a study investigated ABO and Rhesus (Rh) blood group types in children with COVID-19 infection yet. Therefore, the study aimed to examine if such a correlation exists in children infected with COVID-19.
- Conditions
- COVID-19 Infection
- Keywords
- COVID-19, ABO blood group, infection risk
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient medical files
ABO blood type distribution will be different in COVID-19
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2020
- Study start30 Jan 2021
- Primary completionFeb 2021 (estimated)
- Study completionFeb 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19 InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mersin Training and Research Hospital
- Sponsor type
- Other government
- Collaborators
- Mersin University, Dicle University, Bezmialem Vakif University, Uludag University
- Responsible party
- Principal investigator, Ali Özdemir, Mersin Training and Research Hospital
- Investigators
- Ali̇ Özdemi̇r, MD, Principal investigator, Mersi̇n Şehi̇r Eği̇ti̇m Ve Araşti̇rma Hastanesi̇Ali̇ Özdemi̇r, Principal investigator, Mersi̇n Şehi̇r Eği̇ti̇m Ve Araşti̇rma Hastanesi̇
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04682912
- Sponsor's protocol ID
- MersinTRH
- Status last verified
- Jan 2021
- First submitted
- 22 Dec 2020
- Last updated
- 3 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ABO-Rh Blood Types and COVID-19 Infection in Children: Is There a Link?
- ClinicalTrials.gov ID
- NCT04682912
- Acronym / sponsor ID
- MersinTRH
- Conditions
- COVID-19 Infection
- Keywords
- COVID-19, ABO blood group, infection risk
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Mersin Training and Research HospitalOther government
- Collaborators
- Mersin University, Dicle University, Bezmialem Vakif University, Uludag University
- Study start
- 30 Jan 2021 (actual)
- Primary completion
- Feb 2021 (estimated)
- Study completion
- Feb 2021 (estimated)
- First posted
- 24 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is speculated that in adult patients with COVID-19 blood type A is associated with the worst outcome, while blood type O is associated with mild symptoms.To our knowledge, there has been no such a study investigated ABO and Rhesus (Rh) blood group types in children with COVID-19 infection yet. Therefore, the study aimed to examine if such a correlation exists in children infected with COVID-19.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 1 month to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- A retrospective multicenter trial in five major hospitals in Turkey to determine whether ABO and Rh blood types carry any risk/beneficial factor among children with COVID-19 infection.
Key inclusion criteria (2 listed)
- The study period consisted between March 2020 and December 2020
- Children with a documented positive COVID-19 nasal smear real-time reverse-transcriptase polymerase chain reaction (PCR) assay were included.
Key exclusion criteria (1 listed)
- Patients who had a past medical history of any chronic illness (related to respiratory, cardiology, immunology, neurology, metabolic, etc) were excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patient medical files
Time frame: 1 month
ABO blood type distribution will be different in COVID-19
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2021.
Related trials for COVID-19 Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ali̇ Özdemi̇r, MD principal investigator
Mersi̇n Şehi̇r Eği̇ti̇m Ve Araşti̇rma Hastanesi̇
Ali̇ Özdemi̇r principal investigator
Mersi̇n Şehi̇r Eği̇ti̇m Ve Araşti̇rma Hastanesi̇
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 Infection, run by Mersin Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ali̇ Özdemi̇r, MD (03242251000, aliozdemir@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient medical files (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2021.